Related Experiment Videos
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors
1Division of Neurological Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Abstract:
BACKGROUND: Antisense oligodeoxynucleotides (ODNs) have been proposed as a new therapy for patients with cancer, including malignant brain tumors. Antisense ODNs are taken up by tumor cells and selectively block gene expression. Use of ODNs for brain tumors is attractive due to their theoretical specificity, relative ease of production and, to date, paucity of reported adverse effects. This article presents current information regarding antisense ODNs and their possible future use for the treatment of brain tumors. METHODS: The available published experimental and clinical information regarding antisense ODN treatment of glioblastoma cells and administration into the central nervous system (CNS) was reviewed. Other clinically relevant information pertaining to the molecular biology of antisense ODNs was also collected and summarized. RESULTS: Targets for antisense ODN therapy in malignant glioma cells have included c-myc, c-myb, c-sis, c-erb B, CD44, p34cdc2, bFGF, PDGF, TGF-beta, IGF-1, PKC-alpha tumor necrosis factor, urokinase, and S100beta protein. Few in vivo studies of ODN treatment of brain tumors have yet been reported. Systemically administered ODNs enter the brain only in extremely small quantities; therefore, microinfusion into the brain has been recommended. CONCLUSIONS: Antisense ODNs have been used successfully to block glioblastoma gene expression in vitro and expression of multiple genes within the CNS of experimental animals. Upcoming clinical trials will address the safety of antisense ODN use against malignant brain tumors.
Insights
Antisense oligodeoxynucleotides (ODNs) show promise for treating brain tumors by selectively blocking gene expression. Further research and clinical trials are needed to confirm their safety and efficacy in patients.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Antisense oligodeoxynucleotides (ODNs) are being explored as a novel cancer therapy, particularly for malignant brain tumors.
- Their ability to selectively inhibit gene expression in tumor cells offers theoretical specificity and a favorable safety profile.
- This review synthesizes current knowledge on ODNs for brain tumor treatment.
Purpose of the Study:
- To review existing experimental and clinical data on antisense ODN therapy for glioblastoma.
- To summarize the molecular biology of antisense ODNs relevant to central nervous system (CNS) applications.
- To discuss the potential future use of ODNs in treating brain tumors.
Main Methods:
- Literature review of published experimental and clinical studies on antisense ODN treatment of glioblastoma cells.
- Review of studies on ODN administration into the CNS.
- Compilation of data on the molecular mechanisms of antisense ODN action.
Main Results:
- Multiple gene targets in malignant glioma cells have been identified for antisense ODN therapy, including oncogenes and growth factors.
- In vitro studies demonstrate successful blockade of glioblastoma gene expression by ODNs.
- Limited in vivo studies exist, with systemic ODN delivery to the brain being inefficient; microinfusion is recommended.
Conclusions:
- Antisense ODNs can effectively inhibit glioblastoma gene expression in vitro and gene expression in the CNS of experimental animals.
- Clinical trials are forthcoming to evaluate the safety of antisense ODN therapy for malignant brain tumors.
- ODNs represent a promising, targeted approach for brain tumor treatment.